[PE1] Poster Session 1
Adult airway diseases

[PE1-7] Baseline characteristics from phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

David Muccino¹, Masashi Kikuchi², Alyn H Morice³, Surinder S Birring⁴, Lorcan McGarvey⁵, Peter V Dicpinigaitis⁶, Ian D Pavord⁷, Carmen La Rosa¹, Christopher Assaid¹, Jaclyn A Smith⁸ (1.Merck & Co., Inc., USA, 2.MSD K.K., Japan, 3.Hull York Medical School, UK, 4.Division of Asthma, Allergy and Lung Biology, King's College London, UK, 5.Centre for Experimental Medicine, Queen's University Belfast, UK, 6.Albert Einstein College of Medicine and Montefiore Medical Center, UK, 7.Oxford NIHR Respiratory BRC, Nuffield Department of Medicine, University of Oxford, UK, 8.Division of Infection, Immunity and Respiratory Medicine, University of Manchester, UK)